BLUE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 13, 2021 in the Class Action Filed on Behalf of bluebird bio, Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - February 18, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) alleging that the Company violated federal securities laws.
Class Period: May 11, 2020 and November 4, 2020
Lead Plaintiff Deadline: April 13, 2021
Learn more about your recoverable losses in BLUE:
The filed complaint alleges that bluebird bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders have until April 13, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
For additional information about the BLUE lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/74861